论文部分内容阅读
目的研究分析在晚期转移性结直肠癌维持治疗中应用替吉奥的价值。方法晚期转移性结直肠癌患者30例,随机分为观察组与对照组,各15例。对照组患者予以常规支持治疗措施,观察组患者予以替吉奥维持治疗措施,对比分析两组患者的疾病进展时间(TTP)与不良反应发生情况。结果经过治疗,观察组患者的TTP为(9.7±2.3)个月,对照组患者的TTP为(6.1±0.8)个月,两组对比差异具有统计学意义(t=5.7256,P=0.0000<0.05)。两组的30例患者均未发生严重的不良反应且没有中断治疗过程,对疾病的进展及后续治疗没有产生影响。观察组患者中7例出现不良反应的患者经有效的治疗后恢复正常:3例患者出现Ⅰ~Ⅱ度白细胞下降反应,比例为20.0%;2例患者出现Ⅰ~Ⅱ度血小板下降反应,比例为13.3%;1例患者出现Ⅰ度腹泻反应,比例为6.7%;1例患者出现Ⅰ度恶心、呕吐反应,比例为6.7%。结论应用替吉奥维持治疗晚期转移性结直肠癌可有效延长无疾病的进展时间,并且具有较理想的耐受性,临床应用价值较高。
Objective To study the value of using Teglitazone in the maintenance of advanced metastatic colorectal cancer. Methods Thirty patients with advanced metastatic colorectal cancer were randomly divided into observation group and control group, with 15 cases in each group. The patients in the control group were given routine supportive treatment measures. The patients in the observation group were treated for the maintenance of treatment of Gio, and the comparative analysis of the disease progression time (TTP) and adverse reactions between the two groups were compared. Results After treatment, the TTP in the observation group was (9.7 ± 2.3) months and in the control group (6.1 ± 0.8) months, the difference was statistically significant (t = 5.7256, P = 0.0000 <0.05 ). Thirty patients in both groups had no serious adverse reactions and did not interrupt the course of treatment, with no effect on the progression of the disease and subsequent treatment. In the observation group, 7 patients with adverse reactions returned to normal after effective treatment: Ⅰ ~ Ⅱ leukopenia reaction occurred in 3 patients, the proportion was 20.0%; 2 patients had Ⅰ ~ Ⅱ thrombocytopenia response, the ratio was 13.3%. One patient had Grade Ⅰ diarrhea with a rate of 6.7%. One patient had grade Ⅰ nausea and vomiting with a rate of 6.7%. Conclusions The application of TIGO for the treatment of advanced metastatic colorectal cancer can effectively prolong the progression-free time, have better tolerability and higher clinical value.